Zasocitinib clinical trials
Also written TAK-279 and NDI-034858.
How each study uses zasocitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zasocitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2024 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 3 in phase 3
Studies that test zasocitinib, phase 3 first.
- May 2027A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPhase 3 · Takeda
- May 2027A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesPhase 3 · Takeda
- May 2027A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisPhase 3 · Takeda
- Feb 2027A Study of Zasocitinib in Adults With Hidradenitis SuppurativaPhase 2 · Takeda
- Feb 2027A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseasePhase 2 · Takeda
- Mar 2027A Study of Zasocitinib in Adults With Nonsegmental VitiligoPhase 2 · Takeda
Studies
Open first, then newest update. How each study uses zasocitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisRecruitingPhase 3TakedaNCT07250802Written as Zasocitinib
- Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisRecruitingPhase 3TakedaNCT07286058Written as Zasocitinib
- A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisNot yet recruitingPhase 3TakedaNCT07752108Written as Zasocitinib
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 2TakedaNCT06233461Written as TAK-279
- A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)Not yet recruitingPhase 3TakedaNCT07871721Written as Zasocitinib
- A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's DiseaseRecruitingPhase 2TakedaNCT07403968Written as Zasocitinib
- A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)RecruitingPhase 2TakedaNCT06764615Written as Zasocitinib
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesActive, not recruitingPhase 3TakedaNCT06671483Written as Zasocitinib
- A Study of Zasocitinib in Adults With Hidradenitis SuppurativaActive, not recruitingPhase 2TakedaNCT07244263Written as Zasocitinib (Dose A)
- A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedPhase 3TakedaNCT06323356Written as TAK-279
- A Study of Zasocitinib in Adults With Nonsegmental VitiligoActive, not recruitingPhase 2TakedaNCT07108283Written as Zasocitinib
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesActive, not recruitingPhase 3TakedaNCT06671496Written as Zasocitinib
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 2TakedaNCT06254950Written as TAK-279
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisActive, not recruitingPhase 3TakedaNCT06550076Written as TAK-279
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisCompletedPhase 3TakedaNCT06973291Written as Zasocitinib
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodCompletedPhase 3TakedaNCT06108544Written as TAK-279
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentCompletedPhase 3TakedaNCT06088043Written as TAK-279
- A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy AdultsCompletedPhase 1TakedaNCT06793943Written as Zasocitinib
- A Study of TAK-279 in Adults With or Without Liver DamageCompletedPhase 1TakedaNCT05976321Written as TAK-279
- A Study of TAK-279 in Healthy Chinese AdultsCompletedPhase 1TakedaNCT06111547Written as TAK-279
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Codes
What other systems call zasocitinib · ClinicalTrials.gg INT016156
- UNII (FDA) C293MNS6TQZASOCITINIBOne source FDA
- NCI Thesaurus C199133ZasocitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C293MNS6TQ | ZASOCITINIB | One source FDA |
| NCI Thesaurus | C199133 | Zasocitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.